Cadila Healthcare rises on receiving approval for phase 1 clinical trial of ZYIL1

Indian pharmaceutical company, Cadila Healthcare announced on Monday that it has received approval to commence the phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate.

NLRP3 inflammasomes are involved in the inflammation process by the production and release of proinflammatory cytokines. According to the studies, it has been revealed that ZYIL1 can selectively repress the inflammation caused by the NLRP3 inflammasome.

In phase 1 clinical trial, the company will study the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 in healthy human volunteers.

Cadila Healthcare manufactures and markets a huge range of healthcare therapies, including small molecule drugs, biologic therapeutics & vaccines. On the therapeutic front, the company earns 15 per cent from anti-infective and cardiac each, 11 per cent from gastrointestinal and respiratory, 10 per cent from pain management, 8 per cent from gynaecology, 7 per cent from dermatology and 23 per cent from other areas.

At 12.30 pm today, the share of Cadila Healthcare Ltd was trading higher by 0.91 per cent at Rs 475.3. It recorded an intraday high of Rs 480.70 and an intraday low of Rs 466.75 on BSE.